Molly Harper joined our Board in June 2021 and will become our Lead Independent Director upon Mr. O Keeffe s retirement from the Board at the Annual Meeting. Ms. Harper has more than two decades of leading biopharma businesses in growth across settings ranging from large biopharmaceutical companies to entrepreneurial start-ups, with a particular focus on therapeutics for rare diseases. Ms. Harper is currently Managing Partner for Peacock Hall LLC, an advisory firm focused on life sciences companies. Previously, from September 2021 until March 2024, Ms. Harper served as Chief Business Officer for Synlogic, Inc. a clinical-stage biotechnology company pioneering therapeutics based on synthetic biology, where her responsibilities spanned business development, investor relations and corporate communications, new product planning, commercial strategy and patient advocacy. Ms. Harper joined Synlogic from Relmada Therapeutics, Inc., where she was Executive Vice President of Operations from May 2020 to September 2021. Prior to Relmada she served in positions of increasing responsibility with Akcea Therapeutics, most recently as Senior Vice President and Global Franchise General Manager, with responsibility for a six-drug portfolio, including the global commercialization of two rare disease drugs, having designed and built a scalable, global commercial organization. Ms. Harper previously served as Head of US Endocrinology in the Rare Disease division of Sanofi Genzyme, in commercial leadership roles with Merck & Co, and began her career in equity research at UBS Warburg and strategy consulting at The Wilkerson Group/IBM. Ms. Harper received her Bachelor of Arts from Cornell University and her Master of Business Administration from The Wharton School of the University of Pennsylvania. Ms. Harper also serves on the Board of Directors of PreciseDx, a privately held AI oncology pathology company. The Board believes that the characteristics that qualify Ms. Harper to be a director of our company include her significant pharmaceutical industry experience and her experience in pharmaceutical company operations overseeing the development, launch, and commercialization of several pharmaceutical products, including several products that are used to treat orphan/rare diseases, as well as business development and investor relations in the biopharma space.